Psilocybin Therapy for Depression: What a Meta‐Analysis Reveals
TLDR
A systematic review of six randomized trials shows that a standard dose of psilocybin (≈25 mg) combined with psychotherapy can reduce depressive symptoms more than various control conditions, with higher response and remission rates in the weeks after treatment. The evidence comes from a small number of studies, shows notable heterogeneity, and reports only short‑term side‑effects such as headache and nausea that resolve within a week.
What the meta‑analysis examined
The analysis pooled data from six randomized controlled trials that compared psilocybin with control conditions (placebo, waiting‑list, niacin, or a low 1 mg dose). Two dose groups were evaluated: a standard dose (~25 mg per session) and a low dose (~10 mg per session). All trials used manualised psilocybin‑assisted psychotherapy.
Key findings (ROSE)
A systematic review and meta‑analysis of six randomized controlled trials examined psilocybin for major depressive disorder (MDD). The authors compared standard‑dose psilocybin (≈25 mg/session) and low‑dose psilocybin (≈10 mg/session) against various control conditions (placebo, waiting‑list, niacin, or 1 mg psilocybin).
Standard‑dose psilocybin was superior to control in reducing depressive symptoms (standardized mean difference = ‑1.05, 95 % CI = ‑1.60 to ‑0.50, p = 0.0002). Sensitivity analyses that excluded waiting‑list controls still showed a benefit (SMD = ‑0.70, 95 % CI = ‑1.03 to ‑0.36, p < 0.0001). It also increased response rates (RR = 2.34, 95 % CI = 1.52‑3.60, p = 0.0001) and remission rates at 2‑3 weeks (RR = 3.38, 95 % CI = 1.88‑6.08, p < 0.0001) and response at 6‑12 weeks (RR = 2.61, 95 % CI = 1.45‑4.71, p = 0.001). Discontinuation was lower (RR = 0.39, 95 % CI = 0.18‑0.87, p = 0.02). Adverse events included a higher incidence of headache (RR = 2.06, 95 % CI = 1.11‑3.81, p = 0.02) and nausea (RR = 10.20, 95 % CI = 3.80‑27.39, p < 0.0001), which resolved after 1‑9 days. Low‑dose psilocybin showed no superior efficacy versus control.
Evidence grade A indicates a meta‑analysis of randomized trials, which is high quality. However, the primary analysis had substantial heterogeneity (I² = 75 %); sensitivity analyses reduced this to I² = 43 % or 0 % in some outcomes. Only six trials were included, and the overall sample size and detailed participant characteristics are not provided, limiting the precision of the estimates.
In short, a standard dose of psilocybin appears to reduce depressive symptoms more than controls in the weeks following treatment, with a higher chance of achieving response or remission and fewer people dropping out. The drug can cause headaches and nausea, but these side‑effects tend to disappear within a week. This does not prove that psilocybin is a long‑term cure for depression, that it works for every patient, or that it is safe for all populations. More research with larger, consistent trials is needed to confirm these findings and to clarify who might benefit most.
What it does NOT prove
- Long‑term efficacy: The meta‑analysis covers outcomes up to 12 weeks; it does not show sustained benefit beyond that period.
- Universal effectiveness: The trials included a limited number of participants, so the findings cannot be generalized to all people with major depressive disorder.
- Safety for all populations: Only short‑term adverse events were reported; the study does not address risks in vulnerable groups (e.g., pregnant women, people with cardiovascular disease).
- Regulatory approval: The data do not reflect any official approval or guideline endorsement for psilocybin therapy.
Evidence at a glance
| Grade | Risk | Confidence |
|---|---|---|
| A | High | The meta‑analysis is based on randomized trials, but the small number of studies and heterogeneity reduce certainty. |
Conclusion
The pooled evidence from six randomized trials suggests that a standard dose of psilocybin, delivered with psychotherapy, may produce clinically meaningful reductions in depressive symptoms and higher response and remission rates compared to controls, with manageable short‑term side effects. Nonetheless, the limited sample size, methodological differences, and lack of long‑term data mean that these results should be interpreted cautiously. Further large‑scale, well‑controlled studies are needed to determine the durability of benefits, identify which patients might benefit most, and clarify safety across diverse populations.
What is psilocybin therapy?
Psilocybin therapy combines a psychedelic compound, psilocybin, with guided psychotherapy to potentially alleviate psychiatric symptoms. It is studied in controlled research settings, not as an over‑the‑counter remedy.
How does the standard dose compare to the low dose?
The meta‑analysis found that the standard dose (~25 mg) was associated with significant symptom improvement and higher response rates, whereas the low dose (~10 mg) did not show superior efficacy over controls.
What side effects were reported?
Participants receiving the standard dose reported higher rates of headache and nausea in the first 1‑9 days after treatment, but these symptoms resolved within that period.
Does the study say anything about long‑term effects?
No. The longest follow‑up reported was 12 weeks; the analysis does not provide evidence for sustained benefit beyond that timeframe.
Is psilocybin therapy approved for treating depression?
No. While the evidence is promising, psilocybin remains a controlled substance in most jurisdictions and is not approved as a standard treatment for depression.
- Psilocybin and Anxiety – Link to our article on psilocybin’s effects on anxiety disorders.
- Mechanism of Action of Psilocybin – Link to a deep dive into how psilocybin interacts with serotonin receptors.
- Legal Status of Psilocybin – Link to a comprehensive overview of psilocybin’s legal landscape.
- Psilocybin vs. MDMA Therapy – Link to a comparative review of psychedelic‑assisted therapies.
- Psilocybin Research Pipeline – Link to our roadmap of upcoming clinical trials.
Educational Disclaimer
This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
